New data suggest that individuals who were previously vaccinated with Mencevax ACWY™ but remain at high risk of exposure to serogroups A, W-135 and Y should be considered for earlier revaccination

GlaxoSmithKline (GSK) would like to inform healthcare professionals of the new antibody persistence data for Mencevax ACWY™.  The immunity to serogroups W-135 and Y in individuals 11-55 years of age who were vaccinated two years earlier with Mencevax ACWY™ is 24.0% and 44.0%, respectively. Limited data showed a waning of serum bactericidal antibody titres against serogroup A one year post-vaccination when using human complement in the assay (hSBA). Individuals remaining at high risk of exposure to serogroups A, W-135 and Y should be considered for earlier revaccination according to local recommendations. It is to be noted that re-vaccination with group C polysaccharide-containing vaccines may induce lower antibody responses to meningococcal group C polysaccharide compared to primary vaccination. The product information for Mencevax ACWY™ will be updated to include these new antibody persistence data. Please refer to the letter for more details. 

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.